From the 8k:
"The Company believes it currently has
From the 8k:
"The Company believes it currently has enough drug product and substance to complete its contemplated clinical activity and will be transitioning the aforementioned services to one, or several, of its current service providers."
I remember the back and forth posts about the technology transfer wording in the original FAQ's that CYDY posted. Or maybe it was a 10k, or something else, that kicked off the discussion. The most optimistic of the bunch claimed that they were moving the production of LL to a big pharma partner and we'd be finding out who in short order through a big announcement. That obviously didn't happen. The more pessimistic amongst us thought that it was just a wording thing. That nothing had substantially changed or we'd have heard otherwise.
An additional nugget or two was turned over by those always watching and posting, but that whole discussion dissipated over time.
I'd argue that the last sentence in the Samsung filing may have been our best indication yet that more is happening behind the scenes than we are usually allowed to see.
To be clear, I don't think this means we're getting some big announcement any second now. But I do think it bolsters the argument that even though it has taken a long time to get off hold and many of us are/were disappointed that there wasn't some more immediate announcements after the hold was lifted, that things are absolutely bubbling below the surface.
I keep having this suspicious gut feeling that the immune trial doesn't start until after something more substantial goes down. Is it the Amarex settlement we all anticipate? Is it a partner stepping in to own a piece of LL's indications? Is it a buyout (least likely at these prices, in my humble opinion)? Or is it nothing, and they'll get the trial started within a few months as anticipated?
Regardless, I was happy to see the agreement with Samsung for a few reasons. But mainly because it means Samsung feels confident that waiting a little longer will get them far more money than pushing for immediate cash. How would they know that? Through discussions with Cytodyn and a look under the covers.
Things don't necessarily look amazing on the surface right now, but it's what's underneath that matters.
And Cytodyn is a grower, not a show-er.
24
CytoDyn Inc (CYDY) Stock Research Links
Scroll down for more posts ▼
Top 10 Most Recent News Articles
Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....
Continue Reading
August Put the Story Under a Harsh Light Two ugly August trading sessions are doing a lot of work in the case now confronting D-Wave Quantum. The company sits in a field that attracts big dreams, big headlines, and, frankly, plenty of investor imagination. But imagination does not cushion a portfolio when expectations crack. The lawsuits concern people who bought or...
Continue Reading
By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...
Continue Reading
A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...
Continue Reading
Ankles leave little clues after a long day: sock grooves, puffiness, that dull heaviness nobody bothers to name. PureHealth Research wants people to look past the usual salt-and-water explanation and consider the lymphatic system, the body’s comparatively unsung network for gathering fluid from tissues and returning it to the bloodstream. Fair enough. This system does...
Continue Reading
Silence is cheap right up until a company needs talent again. Then the unanswered email, abandoned interview loop, or vanished promise of next steps comes back with a price tag—maybe not neatly labeled in a quarterly filing, but real all the same. LiveCareer’s April 14, 2026 survey of 1,008 employed U.S. adults lands on an uncomfortable point: candidates remember...
Continue Reading
A laboratory notebook is about to become the real product in this AI experiment. Human Frontier Mission, or HFM, says it will launch globally on Nov. 24, opening a research program where domain specialists frame scientific and engineering problems while autonomous AI agents develop and test possible answers. The unusual bit is not merely handing models difficult work. It...
Continue Reading
Six very sick lymphoma patients are not a victory lap, but they can still make the whole cell-therapy field sit up straighter. CARsgen has disclosed first clinical results for CT1182, an in vivo CAR-T candidate built on its CARvivo platform, and the early package is plainly more interesting than the usual preclinical chest-thumping. The company reported three complete...
Continue Reading
Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...
Continue Reading
Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...
Continue Reading
Top 5 Most Recently Viewed Articles
WisdomTree Fund Prices Overview In today’s ever-evolving financial landscape, understanding fund prices is crucial for investors. WisdomTree Issuer plc offers a range of funds that are pivotal to the investment strategy of many. With the latest updates from the fund market, let's delve into the details of some notable WisdomTree funds available for investment. Key...
Continue Reading
Understanding the Proposed Drug Tariffs Introduced by the Administration Recent discussions have centered around proposed 100% tariffs on foreign pharmaceuticals, primarily advocated by the administration. Economists warn that these tariffs will place a heavy financial burden on American patients and insurers rather than the foreign drug manufacturers. Economic Insights...
Continue Reading
AvidXchange Reports Strong Financial Growth in Q2 2025 AvidXchange Holdings, Inc. (Nasdaq: AVDX), a leader in accounts payable (AP) automation software, has published its financial results for the second quarter ended June 30, 2025. The company showcases growth despite various strategic changes, particularly surrounding its pending acquisition. Financial Highlights for Q2...
Continue Reading
Talkiatry Achieves Recognition in Digital Health Talkiatry has been honored as the sixth most innovative digital health startup for 2024. This accolade is a testament to the significant impact the organization is making in the field of behavioral health care. Significance of the CB Insights Ranking Chosen by CB Insights, Talkiatry's ranking reflects a combination of...
Continue Reading
BizBuySell and LoanBud Collaboration Enhances Financing for Businesses BizBuySell, the leading business-for-sale marketplace, has teamed up with LoanBud, a fintech innovator specializing in SBA financing. This collaboration significantly transforms the experience of buying or selling small businesses by increasing transparency and clarity in the financing process from the...
Continue Reading